On March 22, 2026 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in upcoming investor relations events and provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Darovasertib Phase 2/3 OptimUM-02 Trial Topline Results Investor and Analyst Webcast:
Updated Topline Results Guidance: The database lock is projected in the first half of April, followed by the topline data analysis thereafter
Live investor and analyst webcast will be hosted by IDEAYA management and a guest key opinion leader
Pre-registration will be available prior to the event through IDEAYA’s investor relations events page at View Source
Bank of America Merrill Lynch Health Care Conference
Tuesday, May 12th, 2026
Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Bank of America
Stifel 2026 Targeted Oncology Virtual Forum
Tuesday, May 19th, 2026
Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Laura Prendergast, Managing Director, PhD
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at View Source and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
(Press release, Ideaya Biosciences, MAR 22, 2026, View Source [SID1234663806])